Migraine Drug That Blocks the Peptide CGRP Unexpectedly Cleared Stubborn Cystic Acne | Research

The takeaway

A 30-year-old woman's treatment-resistant cystic acne cleared almost entirely within four weeks of starting rimegepant, a CGRP receptor antagonist prescribed for migraines.

4 weeks to clearance
Treatment-resistant cystic acne that had failed antibiotics and hormonal therapy cleared almost entirely within just 4 weeks of starting rimegepant — a CGRP antagonist prescribed for migraines, not acne.

What the researchers found

A 30-year-old woman with treatment-resistant cystic acne and PCOS experienced near-complete clearance of her cystic acne within 4 weeks of starting rimegepant (a CGRP receptor antagonist) for migraine management. Key details:

- Previous failed treatments: antibiotics and hormonal therapy

- Most affected area (chin) cleared almost entirely

- Both cosmetic and physical discomfort (painful lesions) resolved

- Acne did not recur, except for a minor episode during high stress

- The improvement was an unexpected secondary benefit of migraine treatment

The proposed mechanism involves CGRP's role in neurogenic inflammation and its effects on sebaceous gland activity, both of which contribute to acne pathology.

Why it matters

Cystic acne affects millions of people and can be extremely difficult to treat — particularly when it resists standard therapies like antibiotics and hormonal treatments. This case suggests that CGRP, a neuropeptide already targeted by FDA-approved migraine drugs, may be a viable target for acne treatment. If confirmed in larger studies, CGRP antagonists could offer a new therapeutic option for patients with inflammatory skin conditions who have exhausted current treatments.

How the study worked

Single case report documenting the clinical course of a patient who incidentally experienced acne improvement while taking rimegepant for migraine. The patient's treatment history, timeline of improvement, and subsequent course were documented.

What this study cannot tell us

This is a single case report — the weakest form of clinical evidence. The improvement could be coincidental or related to other factors. No control group, blinding, or objective acne scoring was used. The patient had PCOS, which complicates the acne picture. Stress-related minor recurrence suggests the underlying condition was not fully resolved. One case cannot establish CGRP inhibition as an acne treatment.

How to read the evidence

This is a single case report, representing the lowest level of clinical evidence. While the temporal relationship and biological plausibility (CGRP's role in neurogenic inflammation) are suggestive, one case cannot establish efficacy. It serves as a hypothesis-generating observation that warrants controlled studies.

When this study was published

Published in 2025, this is a very recent case report that adds to the emerging interest in repurposing CGRP antagonists for conditions beyond migraine.

The bigger picture

CGRP antagonists (gepants) and anti-CGRP antibodies have revolutionized migraine treatment. This case adds to growing evidence that blocking CGRP may have benefits beyond headache — including for inflammatory skin conditions, rosacea, and potentially other neurogenic inflammatory diseases. The shared role of CGRP in both migraines and skin inflammation makes biological sense, as CGRP is a key mediator of neurogenic inflammation throughout the body.

Questions still open

Would CGRP antagonists like rimegepant show efficacy for cystic acne in a controlled clinical trial?
Is the acne improvement specific to rimegepant, or would other CGRP antagonists (ubrogepant, atogepant) or anti-CGRP antibodies (erenumab) have similar effects?
Could CGRP inhibition become a treatment for other inflammatory skin conditions like rosacea or hidradenitis suppurativa?

Common questions

What is CGRP and how could blocking it help acne?

CGRP (calcitonin gene-related peptide) is a signaling molecule in the nervous system that causes inflammation and blood vessel dilation. It's a major driver of migraines, which is why drugs blocking it were developed for headache treatment. CGRP is also present in the skin, where it contributes to neurogenic inflammation and may affect oil-producing sebaceous glands — both key factors in acne development. Blocking CGRP could reduce the inflammatory component of acne.

Can I get rimegepant prescribed for my acne?

Currently, no. Rimegepant (Nurtec ODT) is only FDA-approved for treating migraines. This is a single case report showing an unexpected acne benefit, not proof that the drug works for acne. Clinical trials would be needed before CGRP antagonists could be recommended or prescribed for skin conditions. However, if you have both migraines and acne, this case suggests you might see skin improvements as a bonus benefit of migraine treatment.

Read the original research

Exploring the Potential Dermatological Benefits of CGRP Inhibition: A Case Report.

Journal of drugs in dermatology : JDD, 24(6), 636-637

View on PubMed ↗Publisher’s paper ↗

Citation

Burke, Olivia M; Cocores, Alexandra; Beer, Jacob; Keri, Jonette E. (2025). Exploring the Potential Dermatological Benefits of CGRP Inhibition: A Case Report.. Journal of drugs in dermatology : JDD, 24(6), 636-637. https://doi.org/10.36849/JDD.8880